Our Mission and Vison
The start of the ATP1A3 in disease Symposia was made in 2012 after the ATP1A3 gene discovery for Alternating Hemiplegia of Childhood. ATP1A3 mutations were already found in 2004 to be associated with a very rare neurological disease rapid-onset dystonia-parkinsonism (RDP) and are now implicated in a growing number of neurological conditions.
The ATP1A3 in disease Symposia bring together prominent scientists, clinicians and family foundations to:
- discuss the role of the ATP1A3 gene in rare neurological diseases.
- present the further progress of the research on AHC, RDP, CA(P)OS and other ATP1A3-related diseases.
- discuss various symptomology and how to address them to improve quality of life for patients now and in respect to clinical trials.
- include new research and clinical teams in the work ongoing.
The start of the ATP1A3 in disease Symposia was made in 2012 after the ATP1A3 gene discovery for Alternating Hemiplegia of Childhood. ATP1A3 mutations were already found in 2004 to be associated with a very rare neurological disease rapid-onset dystonia-parkinsonism (RDP) and are now implicated in a growing number of neurological conditions.
The ATP1A3 in disease Symposia bring together prominent scientists, clinicians and family foundations to:
- discuss the role of the ATP1A3 gene in rare neurological diseases.
- present the further progress of the research on AHC, RDP, CA(P)OS and other ATP1A3-related diseases.
- discuss various symptomology and how to address them to improve quality of life for patients now and in respect to clinical trials.
- include new research and clinical teams in the work ongoing.